Lexicon Pharmaceuticals, Inc (LXRX)

Upgrades Mizuho upgraded the previous rating for Safehold Inc (NYSE:SAFE) from Neutral to Buy. For the second quarter, ...

THE WOODLANDS, Texas, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the issuance and sale of an additional 2,526,540 shares of its common stock, par value $0.001 (the “Common Stock”), pursuant to the full exercise of the underwriters’ option to purchase additional shares in connection with Lexicon’s previously announced public offering of Common Stock. After giving effect to the full exercise of the underwriters’ option to purchase add

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:00 PM. Here's what ...

Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA,with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic Neuropathy, Promising Novel Mechanism of Action in Neuropathic Pain Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2022 and pro

The directors of a company tend to have a unique inside view into the business, so when directors make major buys, investors are wise to take notice. Presumably the only reason a director of a company would choose to take their hard-earned cash and use it to buy stock in the open market, is that they expect to make money — maybe they find the stock very undervalued, or maybe they see exciting progress within the company, or maybe both..

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

U.S. gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Allarity To Shift Focus On ...

Gainers AMTD IDEA Group (NYSE: AMTD) rose 217.3% to $6.60 in pre-market trading after jumping 18% on Monday. The company owns 90%+ ...

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors ...

Looking back to 4 days ago, Lexicon Pharmaceuticals, Inc. (LXRX) priced a 16,843,600 share secondary stock offering at $2.50 per share..

THE WOODLANDS, Texas, July 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET / 4:00 p.m. CT that day to discuss its financial and operating results and to provide a general business update. Dial-in InformationDial-in Number: (888) 886-7786Conference ID: 78319165 Replay InformationDial-in Numb

Gainers Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading. ThermoGenesis Holdings, Inc. ...

Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is ...

Gainers Athersys (NASDAQ:ATHX) stock rose 73.2% to $0.33 during Thursday's regular session. The current volume of ...

Gainers Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) gained 231% to $2.63 on news that the company will be acquired By Henry Crown ...

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approves GSK's ...

Gainers Better Therapeutics (NASDAQ:BTTX) shares moved upwards by 67.3% to $2.56 during Thursday's pre-market ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! It's time for another dive into the biggest pre-market stock movers as we check out what's happening Thursday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” Cash Holders Could Get Hit Hard THIS FRIDAY

THE WOODLANDS, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001 (the “Common Stock”). The shares of Common Stock are being offered at a public offering price of $2.50 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering are expected to be approximately $42.

Gainers JAKKS Pacific, Inc. (NASDAQ: JAKK) rose 34.7% to $23.01 in pre-market trading after the company reported ...

IDEAYA Biosciences (NASDAQ: IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate ...

Gainers Ensysce Biosciences (NASDAQ:ENSC) shares increased by 6.6% to $0.59 during Wednesday's after-market session. This ...

THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001 (the “Common Stock”). In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of Common Stock. There can be no assurance as to whether or when the offering may be compl

The U.S. Food and Drug Administration (FDA) has accepted for review Lexicon Pharmaceuticals ‘ (NASDAQ: LXRX) New Drug Application ...

NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000 PeopleTHE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, for the treatment of heart failure. The FDA assigned a standard review for the NDA filin

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $287.16 per unit.

Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday. Rubicon Technology, Inc. ...

Gainers Nuwellis (NASDAQ:NUWE) stock increased by 52.4% to $0.92 during Tuesday's regular session. Nuwellis's ...